AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 46(6), 1992, pp. 708-710
Copyright © 1992 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franke, E. D.
Right arrow Articles by Wirtz, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franke, E. D.
Right arrow Articles by Wirtz, R. A.

Prevalence of Antibody to the Variant Repeat of the Circumsporozoite Protein of Plasmodium Vivax in Peru

Eileen D. Franke, Carmen M. Lucas, Ervin San Roman AND Robert A. Wirtz
US Naval Medical Research Institute Detachment, Lima, Peru; Occidental Petroleum Corporation of Peru, Andoas, Peru; Department of Entomology, Walter Reed Army Institute of Research, Washington, DC

Individuals living in a malaria-endemic area in northern Peru were found to have antibodies to the variant repeat sequence of the circumsporozoite (CS) protein of Plasmodium vivax. The presence of IgG antibody to the predominant repeat sequence GDRAA/DGQPA represented by the recombinant protein NS181 V20 (V20), and the variant repeat sequence ANGAGNQPG contained in the synthetic peptide Pvk247, was determined by enzyme-linked immunosorbent assay. IgG antibodies to the repeats were present in 78 (26%) of 298 serum samples; 56% of the positive serum samples had antibodies to V20 and 60% had antibodies to Pvk247. These findings stress the importance of considering the variant epitope in designing a vaccine based on the repeat region of the vivax CS protein. In a malaria-endemic area such as the one in this study, in which exposure to the variant repeat epitope may be as frequent as exposure to the predominant repeat, a vaccine based solely on the predominant repeat epitope may be ineffective against the variant form.




This article has been cited by other articles:


Home page
 Infect. Immun.Home page
A. Yadava, J. Sattabongkot, M. A. Washington, L. A. Ware, V. Majam, H. Zheng, S. Kumar, and C. F. Ockenhouse
A Novel Chimeric Plasmodium vivax Circumsporozoite Protein Induces Biologically Functional Antibodies That Recognize both VK210 and VK247 Sporozoites
Infect. Immun., March 1, 2007; 75(3): 1177 - 1185.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Society of Tropical Medicine and Hygiene.